Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Current Deferred Revenue: 2014-2020

Historic Current Deferred Revenue for KalVista Pharmaceuticals (KALV) over the last 3 years, with Jan 2020 value amounting to $1.3 million.

  • KalVista Pharmaceuticals' Current Deferred Revenue fell 89.09% to $1.3 million in Q1 2020 from the same period last year, while for Jan 2020 it was $1.3 million, marking a year-over-year decrease of 89.09%. This contributed to the annual value of $9.5 million for FY2019, which is 48.34% down from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Current Deferred Revenue of $1.3 million as of Q1 2020, which was down 48.37% from $2.6 million recorded in Q4 2019.
  • KalVista Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $20.0 million during Q1 2018, with a 5-year trough of $29,000 in Q1 2016.
  • Moreover, its 3-year median value for Current Deferred Revenue was $12.3 million (2019), whereas its average is $11.4 million.
  • Data for KalVista Pharmaceuticals' Current Deferred Revenue shows a maximum YoY slumped of 89.09% (in 2020) over the last 5 years.
  • Over the past 4 years, KalVista Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $29,000 in 2016, then reached $14.8 million in 2018, then slumped by 82.39% to $2.6 million in 2019, then slumped by 89.09% to $1.3 million in 2020.
  • Its Current Deferred Revenue was $1.3 million in Q1 2020, compared to $2.6 million in Q4 2019 and $6.0 million in Q3 2019.